Ascendis Pharma A/S (ASND) Shares Bought by DAFNA Capital Management LLC
DAFNA Capital Management LLC grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 82.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,214 shares of the biotechnology company’s stock after buying an additional 15,000 shares during the period. DAFNA Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $922,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. FMR LLC increased its position in Ascendis Pharma A/S by 2.7% in the 1st quarter. FMR LLC now owns 3,238,720 shares of the biotechnology company’s stock valued at $90,685,000 after acquiring an additional 86,188 shares during the period. EcoR1 Capital LLC increased its position in shares of Ascendis Pharma A/S by 5.1% during the 1st quarter. EcoR1 Capital LLC now owns 1,025,700 shares of the biotechnology company’s stock valued at $28,720,000 after purchasing an additional 50,000 shares during the period. VHCP Management II LLC boosted its stake in shares of Ascendis Pharma A/S by 21.6% during the 2nd quarter. VHCP Management II LLC now owns 986,492 shares of the biotechnology company’s stock worth $27,385,000 after acquiring an additional 175,000 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth $15,403,000. Finally, OppenheimerFunds Inc. bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth $8,334,000. Institutional investors and hedge funds own 64.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by Marea Informative and is the property of of Marea Informative. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at http://www.mareainformativa.com/ascendis-pharma-as-asnd-shares-bought-by-dafna-capital-management-llc/117559/.
ASND has been the subject of several research reports. Bank of America Corporation raised their price objective on Ascendis Pharma A/S from $36.00 to $46.00 in a research note on Thursday, September 28th. Wells Fargo & Company reaffirmed a “buy” rating and issued a $51.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Credit Suisse Group set a $28.00 target price on Ascendis Pharma A/S and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Leerink Swann reaffirmed a “hold” rating and issued a $28.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, September 1st. Finally, Wedbush reissued an “outperform” rating and set a $10.71 price objective (down previously from $65.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. Ascendis Pharma A/S currently has an average rating of “Hold” and a consensus price target of $36.95.
Ascendis Pharma A/S (ASND) traded down 0.66% during midday trading on Friday, reaching $36.36. The company’s stock had a trading volume of 56,152 shares. Ascendis Pharma A/S has a 52 week low of $17.15 and a 52 week high of $42.00. The firm has a 50 day moving average price of $33.40 and a 200-day moving average price of $33.40. The firm’s market cap is $1.18 billion.
Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 18th. The biotechnology company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.24). Ascendis Pharma A/S had a negative return on equity of 67.76% and a negative net margin of 2,977.70%. The firm had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $0.78 million. During the same quarter last year, the firm posted ($0.53) earnings per share. The firm’s revenue for the quarter was down 61.4% compared to the same quarter last year. On average, analysts forecast that Ascendis Pharma A/S will post ($0.14) earnings per share for the current fiscal year.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Stock Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related stocks with our FREE daily email newsletter.